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INTRODUCTION
Allergen specific immunotherapy is the only curative treat-
ment modality available at present and has been used suc-
cessfully in limited allergic diseases, such as insect venom
allergy, allergic rhinoconjunctivitis (1, 2) and asthma (3-5).
Controlled long-term trials suggest that immunotherapy has
the capacity to modify the natural history of allergic airway
disease by reducing the incidence of new sensitization (6-8),
reducing allergic symptoms through years after discontinu-
ation and preventing the incidence of asthma (1, 2, 4). But
the precise molecular mechanisms underlying this treatment
modality remain elusive. 
Although previous studies were focused on circulating
blocking antibodies (9-11), they could not explain the anti-
gen-specific effects of immunotherapy. Other suggested mech-
anisms were reducing in the numbers of mast cells and eo-
sinophils including the release of mediators (12-14). Recent
studies suggest the modulation of interleukin (IL)-4 and/or
interferon (IFN)-γproduction from allergen-specific T cells
(4, 5, 15-19), especially a decrease in allergen-induced T cell
activation and both Th2 (IL-4, IL-5, and IL-13) and Th1 cyto-
kines (IFN-γ ), which were induced by the increase of regu-
latory T cell cytokine production, such as IL-10 and/or trans-
forming growth factor-β (TGF-β )(20-23).
The hypothesis of our study was that immunotherapy may
induce the functional modification from Th2 to Th1 pheno-
type in T cells, and these changes will be induced in early
phase of rush immunotherapy (RIT) and continued to late
phase. To investigate the modifications of cellular immuni-
ty in the mechanism of RIT, we evaluated the production of
intracellular IL-5 and IFN-γ from the peripheral blood T cells
in the early and late phase of the allergic inflammation in
asthmatic children with and without RIT.
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The Effect of Rush Immunotherapy with House Dust Mite in the 
Production of IL-5 and IFN-γfrom the Peripheral Blood T Cells of
Asthmatic Children
Although the mechanisms are unclear, rush immunotherapy (RIT) may be effec-
tive to treat allergic diseases. We investigated the long-term modifications of cellu-
lar immunity as a mechanism of RIT. The RIT group, included 15 house dust mite
(HDM)-sensitized asthmatic children, received RIT only with Dermatophagoides
farinae (Der f) and Dermatophagoides pteronyssinus (Der p), whereas the control
group, consisted of 10 HDM-sensitized asthmatic children, did not receive RIT. The
asthma symptom scores and the skin reactivities to Der f were measured. The cel-
lular proliferative responses and intracellular interleukin (IL)-5 and interferon (IFN)-γ
productions from peripheral blood T cells were also measured before, 8 weeks and
1 yr after RIT. The symptom scores, skin reactivity to Der f and cellular proliferative
responses to Der f were decreased significantly after 8 weeks and maintained until
1 yr of RIT. The IFN-γ /IL-5 ratio of the CD3(+) and CD4(+) cells were increased sig-
nificantly after 8 weeks and maintained until 1 yr of RIT, while there were no changes
in the control group. These data indicate that the continuous functional modifica-
tion from Th2 to Th1 phenotype of the CD4(+) T cells are developed after RIT in
the asthmatic children sensitized with HDM.
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MATERIALS AND METHODS
Subjects
Twenty five children with atopic asthma (16 boys and 9
girls) who were sensitive only to Dermatophagoides farinae (Der f)
and Dermatophagoides pteronyssinus (Der p) were enrolled. Patients
were divided into two groups, such as those who had received
RIT (n=15, RIT group) and those who had never received
RIT (n=10, control group). 
The diagnosis and severity of asthma were determined for
each patient by the American Thoracic Society guidelines (24).
Asthma was confirmed by a history of dyspnea and wheezing
during the previous 12 months, a greater than 12% reversibili-
ty of forced expiratory volume in one second (FEV1) sponta-
neously or after β 2-agonist inhalation, and/or a methacholine
provocation test result with a PC20 less than 16 mg/mL. All of
the patients were belong to mild to moderate asthma. The
two groups were comparable for the severity of asthma, the
concentration of total immunoglobulin E (IgE) and Der f or
Der p-specific IgE, and allergic skin test to Der f or Der p (Table
1). At the time of the study, all patients were symptom free
(for at least 4 weeks) and did not have any medication for asth-
ma, except for short acting β 2-agonist, for at least 4 weeks
before blood sampling. The ethics committee of the Asan
Medical Center Institutional Review Board approved the
study, and written informed consents were obtained from the
parents of all subjects.
Protocol of rush immunotherapy
The patients received RIT according to the protocol in our
pediatric ward. The patients were admitted for 4 days during
induction period, and the dosages of each injection were rapid-
ly increased in ten-fold daily starting from 5 Therapeutic unit
(TU)/mL. Then they received injections every 2 weeks till 8
weeks until maintenance was achieved (5,000 TU/mL). After
then they received injections every 4 weeks. Allergen extracts
were obtained from Bencard Allergie (Munchen, Germany).
Measurements of symptom scores and skin reactivity to
Der f
The respiratory symptom scores of asthma (25) and the skin
test reactivities (allergen/histamine ratio) to Der f and Der p
were measured. The severity of symptoms was scored on a
Likert scale from 0 to 5 (0=none, 1=trivial, 2=mild, 3=moder-
ate, 4=severe, and 5=very severe). Asthma symptom compla-
ints were divided into three periods: awakening (four items),
daytime (six items), and nighttime (five items). The total num-
bers of nocturnal awakenings for asthma per week were trans-
lated into the same six-point scale as follows: no awakening=
none, 1 awakening=trivial, 2 to 3 awakenings=mild, 4 to 6
awakenings=moderate, 7 to 10 awakenings=severe, and 11
or more awakenings=very severe. 
Lymphocyte proliferation assay
Peripheral blood mononuclear cells (PBMCs) from the pa-
tients were centrifugated by Ficoll-Hypaque gradient (Phar-
macia, Uppsala, Sweden) and were incubated in 96 well round
bottom plate at 106 cells/mL in 200 μ L/well. The dosages of
Der f allergen (Allergopharma, Reinbek, Germany) were 1, 10,
30, and 50 μ g/mL concentration. Proliferative responses were
assayed by tritiated thymidine incorporation after 5 day’s cul-
ture after addition of 1 μ Ci 16 hr before cell harvesting.
Flow cytometric analysis of PBMCs for intracellular
cytokine production
For intracellular T-cell cytokine detection, we employed a
flow cytometry, which has been described elsewhere (26).
PBMCs (107 cells/mL) were stimulated with phorbol myris-
tate acetate (25 ng/mL; Wako, Osaka, Japan) and ionomycin
(1 μ g/mL; Sigma Chemical Co., St. Louis, MO, U.S.A.) in the
presence of 2 mM/L monensin for 4 hr at 37℃ in a humid-
ified atmosphere of 5% CO2 in air. Cells were fixed in 4%
paraformaldehyde and made permeable with saponin. After
blocking with 10% AB serum, cells were incubated with a
monoclonal mouse anti-cytokine antibody (anti-IL-5 and anti-
IFN-γ : Becton-Dickinson, Franklin Lakes, NJ, U.S.A.) at 1
mg/mL in 0.1% saponin. Twenty minutes later, cells were
washed twice and incubated with a fluorescein isothiocyanate-
or phycoerthrin-labeled polyclonal goat anti-mouse isotype
specific antibody and an anti T-cell surface marker antibody
(anti-CD3, anti-CD4, and anti-CD8: Becton-Dickinson) for
30 min. Then cells were analyzed by FACSCalibur (Becton-
Dickinson) and frequency of cytokine-producing cells in dif-
ferent subpopulation was calculated. 
All values are median (range).
P>0.05 between the patients with and without RIT.
RIT, rush immunotherapy; A/H ratio, Allergen/histamine ratio; mon,
month.
Patients with RIT Patients without RIT
Age 10 yr 3 mon 8 yr 9 mon
(7 yr 2 mon-13 yr 6 mon) (7 yr 3 mon-13 yr 1 mon)
Male:female 9:6 7:3
Total eosinophil  580 (210-1,200) 605 (460-1,650)
count (/μ L)
Total IgE (IU/mL) 223 (57.2-1,260) 199 (88.8-1,200)
Der f-IgE (class) 4.40 (2.30-5.00) 4.20 (3.40-5.00)
Der p-IgE (class) 5.00 (3.10-6.10) 5.00 (4.10-6.20)
Der f A/H ratio 2.75 (1.67-4.67) 2.47 (1.55-3.13)
Der p A/H ratio 2.75 (1.56-4.50) 2.55 (1.55-3.88)
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Statistical analysis
Wilcoxon rank sum test was applied to compare the data
of two groups, and Wilcoxon signed rank test was used to
compare the changes of the group before and after RIT. P<
0.05 were regarded as significance.
RESULTS
Respiratory symptom scores and skin test reactivity to
Der f
The respiratory symptom scores were decreased significant-
ly 8 weeks after RIT and maintained until 1 yr after RIT (Fig.
1A), but not in control group (data not shown). In addition,
the skin test reactivity (allergen/histamine ratio) to Der f was
decreased significantly 8 weeks after RIT and maintained
until 1 yr after RIT (Fig. 1B), but not in control group (data
not shown). 
Cellular proliferation assay
The proliferative response was expressed as stimulation index
(SI: cpm with allergen/cpm with medium). The cellular pro-
liferative responses (SI) to each dose of Der f showed dose-de-
pendent responses and the maximum response was found in
the stimulation of Der f 30 μ g/mL concentration. These res-
ponses were decreased significantly 8 weeks after RIT and
maintained until 1 yr after RIT (Fig. 2A). However, in the
control group the cellular proliferative responses were not
suppressed even on 8 weeks and 1 yr follow-up (Fig. 2B).
Changes of T cell population during RIT
By flow cytometry, the frequencies of CD4(+) and CD8(+)
T cells were analyzed before and after RIT. The CD3(+) cells
and CD4(+) cells increased at 8 weeks after RIT, but these
cells decreased at 1 yr after RIT compare to the cell popula-
tion at 8 weeks after RIT (Fig. 3A). In contrast, there were no
significant changes in 3 follow-up periods in the control group
Fig. 1. Respiratory symptom scores (A) and skin test reactivity to Der f (B) were decreased significantly at 8 weeks after RIT and maintained
until 1 yr after RIT in the RIT group, but not in control group.
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Fig. 2. The cellular proliferative responses (stimulation index, SI) were decreased significantly at 8 weeks after RIT (     ) and maintained
until 1 yr after RIT (     ) compared to those before RIT (     ) (A), whereas they were not suppressed in the control group (B). 
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(Fig. 3B). In addition, the CD8(+) cells were not changed at
8 weeks and 1 yr follow-ups in either groups (data not shown). 
Intracellular IFN-γ /IL-5 ratio from the peripheral T cells 
Intracellular IFN-γand IL-5 staining for CD3, CD4, and
CD8 were carried out on activated PBMCs. RIT increased
IFN-γ /IL-5 ratio from the CD3(+) T cells (data not shown),
and from the CD4(+) T cells at 8 weeks after RIT (P<0.01),
but not from the CD8(+) T cells (data not shown), compared
to those before RIT. IFN-γ /IL-5 ratio was maintained until
1 yr after RIT from the CD4(+) T cells (P<0.01, Fig. 4A),
whereas IFN-γ /IL-5 ratio from the peripheral CD3(+), CD4(+)
or CD8(+) T cells was not changed in each follow-up period
in the control group (Fig. 4B). These results suggest that RIT
induced the modification of cellular immune responses in
the peripheral T cells, such as Th2 to Th1 shift in the periph-
eral CD4(+) T cells. 
DISCUSSION 
This study shows early increase of IFN-γ /IL-5 ratio from
the peripheral blood CD4(+) T cells in children with house
dust mite-sensitized asthma even at 8 weeks after RIT. Addi-
tionally this change of IFN-γ /IL-5 ratio was maintained till
1 yr after RIT, whereas these findings were not detected in
asthmatic children without RIT. These changes were main-
ly originated from increase of IFN-γ production rather than
changes of IL-5 production from the peripheral CD4(+) T
cells regardless of RIT. These findings suggest that the immu-
nologic changes after RIT may start early, especially before
maintenance therapy, and be originated from the production
of the IFN-γ particularly from the CD4(+) T cells, not from
the CD8(+) T cells. In addition, these early changes were main-
tained until 1 yr after RIT. These findings suggest that the
Th1 shift on peripheral blood CD4(+) T cells may be one of
the main functional modifications of allergen specific immu-
notherapy and also this effect may be maintained during im-
Fig. 4. IFN-γ /IL-5 ratio from the peripheral CD4(+) T cells was increased at 8 weeks after RIT compared to before RIT and it was maintained
at 1 yr after RIT (A). It was not changed in each follow-up period in the control group (B).
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ulation at 8 weeks after RIT (A). There were no significant changes during 3 follow-up periods in the control group (B).
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munotherapy. Our data is compatible with some of the pre-
vious reports (4, 5), whereas some reported that IFN-γ increas-
es while IL-4 diminishes (5, 15, 19) and some others showed
that IL-4 was decreased while IFN-γ was not altered (16-18).
In addition, others showed a decrease in both cytokines IFN-γ
and IL-4 (20, 27). However, these variable results for the im-
munologic changes after immunotherapy might depend on
the protocol of immunotherapy, the type of allergen, the time
point of evaluation, the type of stimuli used for cytokine pro-
duction, and the cell sources used.
The most important change in the allergen-specific immune
response during immunotherapy is characterized by a decrease
in allergen-induced T cell activation and the production of
both Th1 and Th2 cytokines, which outlines peripheral T
cell tolerance to allergens. Several studies have shown an in-
crease in regulatory T cells, especially in bee-venom immu-
notherapy (20, 22, 23). T cell tolerance can be directly initi-
ated by the autocrine action of IL-10 (21, 22), which can
inhibit the full maturation of dendritic cell (28). This results
in the long lasting induction of tolerance in both Th1 and
Th2 cells. 
Also, the respiratory symptom were improved significantly
in the early phase of RIT only and that was also maintained
until 1 yr after RIT. In this study, there was good correlation
between the changes of respiratory symptom score and the
changes of IFN-γ (+)/CD4(+) cells. In addition, skin reactiv-
ity to Der f, which means skin mast cell reactivity, was also
significant decrease in the early phase of RIT, and that was
persisted until 1 yr after RIT. These findings suggest that not
only asthma symptoms but also target tissue responsiveness
are improved after RIT, which may be related to the shift of
Th1 immune response or decreased histamine release from
target cells including basophils and mast cells (14).
IFN-γ -production from peripheral CD4(+) T cells was lower
in atopic asthmatics (29). According to these results, immu-
notherapy may induce the shift of cytokine balance from Th2
to Th1 milieu in the systemic circulation. 
RIT suppressed the cellular proliferation in each dose of
Der f, and also this suppression was maintained until 1 yr after
RIT only in RIT group in contrast to control group. These
data were compatible to the previous study (4) which showed
decreased proliferation of peripheral blood mononuclear cells
to relevant allergen (Der p) in early phase of RIT, but not to
irrelevant allergen. Although the inhibition of cellular pro-
liferation underlies the clinical effect of RIT, the mechanism
of RIT is not clear. The possibility may be suggested by the
induction of allergen-specific suppressor T cells (30), the induc-
tion of anergy (31), or the induction of IFN-γ (32).
To confirm the increase of IFN-γproduction from the PB-
MCs after RIT, we also evaluated the serial studies at three
different time points during RIT in 7 patients, such as 8 weeks
before, immediately before, and 8 weeks after RIT. IFN-γ (+)/
CD4(+) T cells were not changed between 8 weeks before
and immediately before RIT, but were increased at 8 weeks
after RIT (P<0.05, data not shown). These data suggest that
IFN-γ (+)/CD4(+) T cells might be increased by the effect of
RIT.
The mechanism of increment of IFN-γproducing cells by
RIT is not defined. The possible mechanism might be ex-
plained by the route of allergen exposure and the amount of
administered allergens, which may alter the function of anti-
gen presenting cells (33). The use of repeated high allergen
concentrations during RIT may lead the shift to the Th1 cell
response. It appears that RIT may correct the decreased IFN-γ
production of CD4(+) T cells in the children with atopic
asthma. 
All our results were originated from the peripheral blood
T cells of the asthmatic patients, therefore these did not reveal
the direct cause and effect of RIT in the asthmatic airway, so
we pointed the systemic effect of RIT. Additionally we sug-
gest that the Th1 shift of immunologic cells may be impor-
tant in the mechanism of RIT. 
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